@article {Zaidati45, author = {Osama O Zaidat and Alicia C Castonguay and Rishi Gupta and Chung-Huan J Sun and Coleman Martin and William E Holloway and Nils Mueller-Kronast and Joey D English and Italo Linfante and Guilherme Dabus and Tim W Malisch and Franklin A Marden and Hormozd Bozorgchami and Andrew Xavier and Ansaar T Rai and Michael T Froehler and Aamir Badruddin and Thanh N Nguyen and M Asif Taqi and Michael G Abraham and Vallabh Janardhan and Hashem Shaltoni and Roberta Novakovic and Albert J Yoo and Alex Abou-Chebl and Peng R Chen and Gavin W Britz and Ritesh Kaushal and Ashish Nanda and Mohammad A Issa and Raul G Nogueira}, editor = {Fitzsimmons, Brian-Fred and Lynch, John R and Lazzaro, Marc A and Lin, Eugene and Samaniego, Edgar and Domico, Jennifer and Sieren, Jeri and Olalde, Heena and Norbash, Alexander M and Masoud, Hesham and Clark, Judith and Wolfe, Tom and Sodhi, Ajeet and Pride, Lee and Rickert, Kim L and Welch, Babu G and White, Jonathan A and Leslie-Mazwi, Thabele M and Hirsch, Joshua A and Sanzgiri, Aditya and Agrawal, Abhishek}, title = {North American Solitaire Stent Retriever Acute Stroke registry: post-marketing revascularization and clinical outcome results}, volume = {10}, number = {Suppl 1}, pages = {i45--i49}, year = {2018}, doi = {10.1136/neurintsurg-2013-010895.rep}, publisher = {British Medical Journal Publishing Group}, abstract = {Background Limited post-marketing data exist on the use of the Solitaire FR device in clinical practice. The North American Solitaire Stent Retriever Acute Stroke (NASA) registry aimed to assess the real world performance of the Solitaire FR device in contrast with the results from the SWIFT (Solitaire with the Intention for Thrombectomy) and TREVO 2 (Trevo versus Merci retrievers for thrombectomy revascularization of large vessel occlusions in acute ischemic stroke) trials.Methods The investigator initiated NASA registry recruited North American sites to submit retrospective angiographic and clinical outcome data on consecutive acute ischemic stroke (AIS) patients treated with the Solitaire FR between March 2012 and February 2013. The primary outcome was a Thrombolysis in Myocardial Ischemia (TIMI) score of >=2 or a Treatment in Cerebral Infarction (TICI) score of >=2a. Secondary outcomes were 90 day modified Rankin Scale (mRS) score, mortality, and symptomatic intracranial hemorrhage.Results 354 patients underwent treatment for AIS using the Solitaire FR device in 24 centers. Mean time from onset to groin puncture was 363.4{\textpm}239 min, mean fluoroscopy time was 32.9{\textpm}25.7 min, and mean procedure time was 100.9{\textpm}57.8 min. Recanalization outcome: TIMI >=2 rate of 83.3\% (315/354) and TICI >=2a rate of 87.5\% (310/354) compared with the operator reported TIMI >=2 rate of 83\% in SWIFT and TICI >=2a rate of 85\% in TREVO 2. Clinical outcome: 42\% (132/315) of NASA patients demonstrated a 90 day mRS <=2 compared with 37\% (SWIFT) and 40\% (TREVO 2). 90 day mortality was 30.2\% (95/315) versus 17.2\% (SWIFT) and 29\% (TREVO 2).Conclusions The NASA registry demonstrated that the Solitaire FR device performance in clinical practice is comparable with the SWIFT and TREVO 2 trial results.}, issn = {1759-8478}, URL = {https://jnis.bmj.com/content/10/Suppl_1/i45}, eprint = {https://jnis.bmj.com/content/10/Suppl_1/i45.full.pdf}, journal = {Journal of NeuroInterventional Surgery} }